Informatie:
Fout:
ID
16068
Beschrijving
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00034255
Link
https://clinicaltrials.gov/show/NCT00034255
Trefwoorden
Versies (1)
- 27-06-16 27-06-16 -
Geüploaded op
27 juni 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Diabetes Mellitus, Type 1 NCT00034255
Eligibility Diabetes Mellitus, Type 1 NCT00034255
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 1 NCT00034255
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
inclusion criteria
Item
patients meeting all of the following inclusion criteria at screening can be considered for admission to the study.
boolean
stage 1 and stage 2:
Item
stage 1 and stage 2:
boolean
age and diabetes type
Item
1. male and female patients with, type 1 diabetes mellitus that are 18 through 70 years of age, or type 2 diabetes mellitus that are 30 through 70 years of age.
boolean
C0001779 (UMLS CUI [1,1])
C0011854 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2,1])
C0011860 (UMLS CUI [2,2])
C0011854 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2,1])
C0011860 (UMLS CUI [2,2])
insulin deficient patients currently well managed
Item
2. patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes mellitus, and are currently well managed with insulin, with or without metformin.
boolean
C1850546 (UMLS CUI [1,1])
C2732401 (UMLS CUI [1,2])
C2733147 (UMLS CUI [2])
C2732401 (UMLS CUI [1,2])
C2733147 (UMLS CUI [2])
stable insulin dose
Item
3. patients who have been on stable doses of insulin treatment for 90 days prior to study randomization.
boolean
C1990777 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,2])
ID.6
Item
patients meeting any of the following exclusion criteria at screening will not be enrolled in the study:
boolean
comorbidities
Item
1. patients with a history of any clinically significant retinopathy, symptomatic autonomic neuropathy, unstable angina, or kidney problems.
boolean
C0262926 (UMLS CUI [1,1])
C0035309 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0442874 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0002965 (UMLS CUI [3,2])
C0262926 (UMLS CUI [4,1])
C0022658 (UMLS CUI [4,2])
C0035309 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0442874 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0002965 (UMLS CUI [3,2])
C0262926 (UMLS CUI [4,1])
C0022658 (UMLS CUI [4,2])
pulmonary, neurological or cardiovascular disease
Item
2. patients with an uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure, angina, or peripheral vascular disease.
boolean
C0024115 (UMLS CUI [1])
C0027765 (UMLS CUI [2])
C0007222 (UMLS CUI [3])
C0027765 (UMLS CUI [2])
C0007222 (UMLS CUI [3])
received any investigational product
Item
3. patients who have received any investigational product within 30 days of admission into the study.
boolean
C2348568 (UMLS CUI [1])
medical history of autoimmune disorders
Item
4. patients with a history or clinical evidence of multiple organ autoimmune disorders.
boolean
C0262926 (UMLS CUI [1,1])
C0004364 (UMLS CUI [1,2])
C0004364 (UMLS CUI [1,2])
medical condition decreasing study compliance
Item
5. patients with a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
breastfeeding
Item
6. patients who are lactating and breastfeeding.
boolean
C0006147 (UMLS CUI [1])